2020-04-29 16:00Financial Performance - Operating revenue for the period was CNY 153,614,830.20, representing a decline of 50.81% year-on-year [4]. - Net profit attributable to shareholders was a loss of CNY 24,855,428.82, a decrease of 137.33% compared to the same period last year [4]. - The net cash flow from operating activities was negative CNY 54,461,823.95, a significant decline of 1,450.97% year-on-year [4]. - Basic and diluted earnings per share were both -CNY 0.14, a decrease of 133.33% compared to the same period last year [4]. - The company's net profit attributable to shareholders was CNY -24.86 million, a decline of 137.33% compared to the previous year [15]. - The company reported a significant drop in sales due to the COVID-19 pandemic, with approximately 70% of revenue coming from mainland China [17]. - The company expects a potential significant change in net profit compared to the previous year due to the ongoing impact of the pandemic [22]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 6,014,270,430.54, a decrease of 2.24% compared to the end of the previous year [4]. - Total current assets amounted to ¥2,662,575,569.56, down from ¥2,772,472,546.50, reflecting a decrease of about 4.0% [27]. - Total liabilities decreased to ¥148,211,316.63 from ¥177,729,022.12, indicating a decline of about 16.6% [29]. - Total equity attributable to shareholders decreased to ¥4,280,337,123.60 from ¥4,287,888,951.10, a slight decrease of approximately 0.2% [29]. Revenue Breakdown - The revenue from ophthalmic products was CNY 74.61 million, accounting for 48.70% of the main business revenue, down 52.85% year-on-year [16]. - The revenue from the aesthetic and wound care products dropped significantly, with a decline of 63.69% year-over-year, totaling CNY 21.47 million [17]. - The orthopedic products revenue decreased by 48.87% year-over-year, amounting to CNY 26.09 million [17]. - The company's operating revenue for the first quarter was CNY 153.61 million, a decrease of CNY 158.68 million or 50.81% compared to the same period last year [13]. Cash Flow - The cash flow from investment activities was negative CNY 83.97 million, a decrease of 408.66% year-over-year [20]. - The company reported a net cash outflow from operating activities of CNY -54,461,823.95 in Q1 2020, compared to a positive cash flow of CNY 4,031,326.33 in Q1 2019 [35]. - The company experienced a net decrease in cash and cash equivalents of -72,714,182.45 RMB in Q1 2020, contrasting with an increase of 87,688,044.16 RMB in Q1 2019 [37]. Expenses - Research and development expenses accounted for 18.46% of operating revenue, an increase of 10.65 percentage points compared to the previous year [5]. - The company's financial expenses increased by CNY 24.73 million, primarily due to increased interest income and foreign exchange gains from the depreciation of the British pound against the US dollar [14]. - The company's tax expenses decreased by 115.05% to CNY -1.67 million, mainly due to losses incurred during the reporting period [15]. Shareholder Information - The total number of shareholders at the end of the reporting period was 8,099 [7]. - The largest shareholder, Jiang Wei, held 44,449,000 shares, representing 24.99% of the total shares [7].